A Study in Subjects With Perennial Allergic Rhinitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00210015
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : January 25, 2016
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
The purpose of this study was to determine the efficacy and safety of the study drug compared to placebo for the treatment of subjects with perennial allergic rhinitis.

Condition or disease Intervention/treatment Phase
Perennial Allergic Rhinitis Drug: INS37217 Nasal Spray Phase 2

Study Type : Interventional  (Clinical Trial)
Enrollment : 630 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Multi-Center, Randomized, Parallel-Group, Double-Blind, Efficacy and Safety Study of INS37217 Nasal Spray Versus Placebo in Subjects With Perennial Allergic Rhinitis
Study Start Date : December 2002
Actual Primary Completion Date : April 2003
Actual Study Completion Date : April 2003

Primary Outcome Measures :
  1. total nasal symptom score

Secondary Outcome Measures :
  1. average total nasal symptom scores over various timepoints average individual symptom scores
  2. global assessment of perennial allergic rhinitis symptoms
  3. instantaneous assessment of symptoms
  4. change from baseline in quality of life assessments
  5. physical and anterior nasal exams
  6. laboratory tests
  7. ECG
  8. vital signs
  9. adverse events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior

Inclusion Criteria:

  • Have a documented history of allergy to perennial allergens and demonstrated sensitivity by the results of prick or intradermal skin testing.
  • Have a self-reported history of at least mild, intermittent rhinorrhea and nasal blockage/stuffiness due to allergies.
  • Have not started or had a change in immunotherapy regimen.

Exclusion Criteria:

  • Have a physical obstruction in the nose.
  • Will likely have an acute increase in severity of allergic rhinitis due to seasonal aeroallergens during the trial.
  • Have acute or chronic sinusitis or had previous sinus surgery resulting in a significant change in the sinus or nasal anatomy.
  • Have rhinitis medicamentosa or any other acute or chronic condition that could confound evaluations of nasal symptoms.
  • Have asthma of sufficient severity to require use of excluded medications.
  • Have taken any medications excluded as listed in the protocol.
  • Have a clinically significant acute or chronic disease or clinically significant laboratory abnormality.
  • Are a current smoker, recent smoker or past smoker as defined in the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00210015

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Amy Schaberg, B.S.N.

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00210015     History of Changes
Other Study ID Numbers: 07-105
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: January 25, 2016
Last Verified: January 2016

Additional relevant MeSH terms:
Rhinitis, Allergic
Rhinitis, Allergic, Perennial
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases